Multidrug resistance in haemopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia

British Journal of Haematology
J HolmesR A Padua


Resistance to cytotoxic agents is a common clinical problem encountered in the treatment of human myelodysplastic syndromes (MDS) and acute myeloblastic leukaemia (AML). Cellular acquisition of the multidrug resistance (MDR) phenotype confers loss of sensitivity to a wide range of structurally dissimilar anti-neoplastic agents. This state can arise through increased expression of the mdrl (P-glycoprotein) gene. We have used the mdrl gene probe to investigate adriamycin resistant (HL60/AR) and vinblastine resistant (CEM/VLB100) human leukaemic cell lines. In addition, peripheral blood or bone marrow cells from 66 patients with MDS and AML have been screened for gene amplification and 40 cases for increased mRNA expression. P-glycoprotein gene amplification was observed only in the (CEM/VLB100) and not in the HL60/AR on any other leukaemic cell line. Gene amplification was not found in any patient's cells. Eighteen out of 40 patients showed an increase (2----20) of mdrl mRNA expression. These results are not only of significance in understanding the biology of human drug resistance but have practical importance in the design of anti-leukaemic therapy.


Jan 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·A T FojoI Pastan
Aug 3, 1988·Biochimica Et Biophysica Acta·G BradleyV Ling
Jan 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·P GrosD E Housman
Nov 1, 1986·Molecular and Cellular Biology·D W ShenM M Gottesman
Jul 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·D DiMaioT Maniatis

❮ Previous
Next ❯


Jan 1, 1993·Cytotechnology·K Nooter, P Sonneveld
Aug 1, 1996·Leukemia Research·P BentleyJ Thomas
Oct 1, 1991·Cancer Genetics and Cytogenetics·A Jacobs
Jun 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J P MarieR Zittoun
May 1, 1996·Critical Reviews in Oncology/hematology·J F San MiguelM A Sanz
Oct 21, 2004·Best Practice & Research. Clinical Haematology·Douglas D Ross
May 1, 1991·Mayo Clinic Proceedings·P Noël
Jun 1, 1990·British Journal of Haematology·P Sonneveld, K Nooter
Jun 1, 1991·British Journal of Haematology·M MichieliM Baccarani
Jan 1, 1991·British Journal of Haematology·J A HolmesA Jacobs
Jun 1, 1992·British Journal of Haematology·J P MarieB I Sikic
Oct 1, 1995·British Journal of Haematology·D A Bradbury, N H Russell
Dec 1, 1992·Annals of Hematology·C F RochlitzR Herrmann
Dec 24, 1997·Leukemia & Lymphoma·G Del PoetaS Amadori
Nov 1, 1996·Leukemia & Lymphoma·R MalayeriR Pirker
Jan 1, 1990·Leukemia & Lymphoma·J A Holmes
Oct 1, 1992·Baillière's Clinical Haematology·P BainesR A Padua
Jul 1, 1991·Baillière's Clinical Haematology·A G Hall, A R Cattan
Jan 1, 1990·Human Pathology·R S WeinsteinJ S Coon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.